PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.
The user shared their 5-month hair regrowth progress using oral finasteride daily, topical minoxidil twice daily, derma stamping weekly, castor oil weekly, and the Nioxin system kit. Replies praised the results and inquired about the timeline and side effects.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.
The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.
Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.
The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.
The user reported positive hair regrowth results after six months of using 0.5 mg finasteride and nanoxidil, despite experiencing initial side effects like testicular pain and changes in libido. They noted that nanoxidil was chosen over minoxidil due to less scalp irritation.
Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
The conversation is about finding a reliable source for oral minoxidil in Turkey, preferably in original packaging, and concerns about the safety and effectiveness of local products. The user is seeking recommendations for trustworthy suppliers and is wary of counterfeit products and scams.
The conversation is about a user's progress with hair regrowth using oral minoxidil and finasteride over two years. The user experienced significant improvement without side effects, except for increased libido, and plans to continue treatment.
Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.
The conversation discusses affordable low-level light therapy (LLLT) products for hair loss, with users debating the effectiveness of red LEDs versus lasers. The original poster is already using finasteride, minoxidil, ketoconazole, and microneedling, and is seeking budget-friendly LLLT options to add to their regimen.
A user shared their positive experience with hair regrowth using 1mg finasteride and 5% topical minoxidil daily, showing significant improvement in hair density over six months. The conversation includes supportive comments and questions about the treatment details, such as whether finasteride was taken orally or topically and if microneedling was used.
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.
MinoxidilMax is now selling a product called Ruderma, which contains RU58841, a chemical used for hair loss treatment. Some users question the legitimacy of the company, while others discuss the standard concentration of RU58841 and mention that both men and women use finasteride for hair loss.
Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.
The user shared progress pictures after using 1mg oral finasteride daily and topical minoxidil every other day for four months, showing significant hair growth. Others congratulated the user and discussed personal experiences with hair loss treatments.
The conversation is about someone switching from Minoxidil and Finasteride to Redensyl, Procapil, and Capixyl serums due to anxiety over potential side effects, and they are inquiring about others' regrowth experiences with these serums. Some doctors in India have prescribed these serums, and the person knows others who are satisfied with the results.
The conversation discusses using minoxidil, finasteride, a dermastamp, and botanical oils like peppermint, rosemary, and pumpkin seed oil for hair growth. The user is considering using Alpha Infuse, which combines microneedling with plant oils, to enhance results.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
A user is considering creating an all-in-one topical solution for hair loss, combining 0.25mg finasteride, 5% minoxidil, and 5% RU58841. They are seeking advice on its feasibility and absorption.
The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.
The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.